IBERDOMIDE

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C25H27N3O5
Molecular Weight	449.499
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of IBERDOMIDE

Structure Search

SMILES

O=C1N(CC2=C1C=CC=C2OCC3=CC=C(CN4CCOCC4)C=C3)[C@H]5CCC(=O)NC5=O

InChI

InChIKey=IXZOHGPZAQLIBH-NRFANRHFSA-N

InChI=1S/C25H27N3O5/c29-23-9-8-21(24(30)26-23)28-15-20-19(25(28)31)2-1-3-22(20)33-16-18-6-4-17(5-7-18)14-27-10-12-32-13-11-27/h1-7,21H,8-16H2,(H,26,29,30)/t21-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C25H27N3O5
Molecular Weight	449.499
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Approval Year

Substance Class	Chemical Created by `admin` on `Sat Dec 16 10:40:42 UTC 2023` Edited by `admin` on `Sat Dec 16 10:40:42 UTC 2023`
Record UNII	8V66F27X44
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

IBERDOMIDE

Official Name

English

Iberdomide [WHO-DD]

Common Name

English

(3S)-3-[4-({4-[(Morpholin-4-yl)methyl]phenyl}methoxy)-1-oxo-1,3-dihydro-2H-isoindol-2-yl]piperidine-2,6-dione

Systematic Name

English

2,6-PIPERIDINEDIONE, 3-(1,3-DIHYDRO-4-((4-(4-MORPHOLINYLMETHYL)PHENYL)METHOXY)-1-OXO-2H-ISOINDOL-2-YL)-, (3S)-

Systematic Name

English

(S)-3-(4-((4-(MORPHOLINOMETHYL)BENZYL)OXY)-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE

Systematic Name

English

iberdomide [INN]

Common Name

English

CC-220

Code

English

IBERDOMIDE [USAN]

Common Name

English

Classification Tree Code System Code

FDA ORPHAN DRUG

665718

Created by admin on Sat Dec 16 10:40:43 UTC 2023 , Edited by admin on Sat Dec 16 10:40:43 UTC 2023

NCI_THESAURUS

C308

Created by admin on Sat Dec 16 10:40:43 UTC 2023 , Edited by admin on Sat Dec 16 10:40:43 UTC 2023

Code System Code Type Description

PUBCHEM

67335295

Created by admin on Sat Dec 16 10:40:43 UTC 2023 , Edited by admin on Sat Dec 16 10:40:43 UTC 2023

PRIMARY

NCI_THESAURUS

C129048

Created by admin on Sat Dec 16 10:40:43 UTC 2023 , Edited by admin on Sat Dec 16 10:40:43 UTC 2023

PRIMARY

USAN

DE-06

Created by admin on Sat Dec 16 10:40:43 UTC 2023 , Edited by admin on Sat Dec 16 10:40:43 UTC 2023

PRIMARY

DRUG BANK

DB12101

Created by admin on Sat Dec 16 10:40:43 UTC 2023 , Edited by admin on Sat Dec 16 10:40:43 UTC 2023

PRIMARY

CAS

1323403-33-3

Created by admin on Sat Dec 16 10:40:43 UTC 2023 , Edited by admin on Sat Dec 16 10:40:43 UTC 2023

PRIMARY

FDA UNII

8V66F27X44

Created by admin on Sat Dec 16 10:40:43 UTC 2023 , Edited by admin on Sat Dec 16 10:40:43 UTC 2023

PRIMARY

SMS_ID

300000025973

Created by admin on Sat Dec 16 10:40:43 UTC 2023 , Edited by admin on Sat Dec 16 10:40:43 UTC 2023

PRIMARY

INN

10632

Created by admin on Sat Dec 16 10:40:43 UTC 2023 , Edited by admin on Sat Dec 16 10:40:43 UTC 2023

PRIMARY

Related Record Type Details


					HR6E2AWX74

CEREBLON

TARGET -> INHIBITOR

Comments:

CRBN ubiquitination studies in the transfected HEK293T cells resulted in the following potencies: CC-220 IC50 = 0.19 μM; lenalidomide IC50 = 12.9 μM; and pomalidomide IC50 = 21.6 μM

Qualification:

IC50

Amount:


					HR6E2AWX74

CEREBLON

TARGET -> INHIBITOR

Comments:

Competitive CRBN binding studies, preincubation with pomalidomide at a concentration of 3 μM resulted in approximately 50% less CRBN bound to the affinity beads, while CC-220 at a concentration of 0.1 μM resulted in similar CRBN binding.

Interaction Type:

BINDING

Qualification:

IC50

Amount:


					79L3645KFI

IBERDOMIDE HYDROCHLORIDE

SALT/SOLVATE -> PARENT

Related Record Type Details


					8V66F27X44

ACTIVE MOIETY